MIRUM PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Laurent Fischer, M.D.

MIRUM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Laurent Fischer, M.D.”): 19,162,293 for, 14,762,966 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 4,441,361 for, 7,087,624 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 208,509 for, 1,204 against.

Description as filed by funds: Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Patrick J. Heron

MIRUM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Heron”): 24,363,371 for, 9,561,888 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 8,291,639 for, 3,237,346 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 208,443 for, 1,204 against.

Description as filed by funds: Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Saira Ramasastry, M.S., M.Phil.

MIRUM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Saira Ramasastry, MS, M.Phil.”): 25,853,444 for, 8,071,815 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 9,552,188 for, 1,976,797 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 208,443 for, 1,204 against.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

MIRUM PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 32,709,274 for, 1,125,532 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 56 managers: 11,413,146 for, 115,839 against, 70,000 withheld. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 147 managers: 21,706,551 for, 445,030 against, 13,090 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 55 managers: 3,321,775 for, 8,206,619 1 year, 591 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 140 managers: 242,960 for, 36 against, 21,600,155 1 year, 809 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

MIRUM PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 37,536,300 for, 36,362 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors (the "Board") of Ernst & Young LLP as the Company's independent registered public accounting firm for the fisca…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 11,528,985 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 352,717 for.